Non-interventional, Post Marketing Surveillance Study of Xultophy™ (Insulin Degludec/Liraglutide) to Evaluate Long Term Safety and Efficacy in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in India - Trial NCT03070704
Access comprehensive clinical trial information for NCT03070704 through Pure Global AI's free database. This phase not specified trial is sponsored by Novo Nordisk A/S and is currently Withdrawn. The study focuses on Diabetes,Diabetes Mellitus, Type 2. Target enrollment is 0 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Novo Nordisk A/S
Timeline & Enrollment
N/A
Aug 16, 2017
Aug 16, 2019
Primary Outcome
Incidence of treatment emergent Adverse Events (AEs)
Summary
This study is conducted in Asia. The aim of this study is to evaluate long term safety and
 efficacy in patients with type 2 diabetes mellitus in routine clinical practice in India.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT03070704
Non-Device Trial